{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:26:07Z","timestamp":1795029967526,"version":"4.10.2"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["UW2020 award"],"award-info":[{"award-number":["UW2020 award"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA014520"],"award-info":[{"award-number":["P30CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["DP5OD024576"],"award-info":[{"award-number":["DP5OD024576"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA233102"],"award-info":[{"award-number":["U01CA233102"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA250972"],"award-info":[{"award-number":["P01CA250972"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radiation therapy (RT) activates an in situ vaccine effect when combined with immune checkpoint blockade (ICB), yet this effect may be limited because RT does not fully optimize tumor antigen presentation or fully overcome suppressive mechanisms in the tumor-immune microenvironment. To overcome this, we develop a multifunctional nanoparticle composed of polylysine, iron oxide, and CpG (PIC) to increase tumor antigen presentation, increase the ratio of M1:M2 tumor-associated macrophages, and enhance stimulation of a type I interferon response in conjunction with RT. In syngeneic immunologically \u201ccold\u201d murine\u00a0tumor models, the combination of RT, PIC, and ICB significantly improves tumor response and overall survival resulting in cure of many mice and consistent activation of tumor-specific immune memory. Combining RT with PIC to elicit a robust in situ vaccine effect presents a simple and readily translatable strategy to potentiate adaptive anti-tumor immunity and augment response to ICB or potentially other immunotherapies.<\/jats:p>","DOI":"10.1038\/s41467-022-32645-x","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T14:03:00Z","timestamp":1661263380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade"],"prefix":"10.1038","volume":"13","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghava N.","family":"Sriramaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Jagodinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhou","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4147-9735","authenticated-orcid":false,"given":"Wonjong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-9229","authenticated-orcid":false,"given":"Caroline P.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raad","family":"Allawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0249-0002","authenticated-orcid":false,"given":"Ruosen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Havighurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishan","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Rakhmilevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Sondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmann","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-2938","authenticated-orcid":false,"given":"Shaoqin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5558-3547","authenticated-orcid":false,"given":"Zachary S.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"32645_CR1","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","volume":"162","author":"DR Littman","year":"2015","unstructured":"Littman, D. R. Releasing the brakes on cancer immunotherapy. Cell 162, 1186\u20131190 (2015).","journal-title":"Cell"},{"key":"32645_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"32645_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","volume":"6","author":"Q Duan","year":"2020","unstructured":"Duan, Q. et al. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 6, 605\u2013618 (2020).","journal-title":"Trends Cancer"},{"key":"32645_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura, P. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10, 168 (2019).","journal-title":"Front. Immunol."},{"key":"32645_CR5","doi-asserted-by":"crossref","unstructured":"Blass, E. et al. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215\u2013229 (2021).","DOI":"10.1038\/s41571-020-00460-2"},{"key":"32645_CR6","doi-asserted-by":"publisher","first-page":"e2007293","DOI":"10.1002\/adma.202007293","volume":"33","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy. Adv. Mater. 33, e2007293 (2021).","journal-title":"Adv. Mater."},{"key":"32645_CR7","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1158\/0008-5472.CAN-15-2644","volume":"76","author":"ZS Morris","year":"2016","unstructured":"Morris, Z. S. et al. In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments. Cancer Res. 76, 3929\u20133941 (2016).","journal-title":"Cancer Res."},{"key":"32645_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","volume":"84","author":"SC Formenti","year":"2012","unstructured":"Formenti, S. C. et al. Radiation therapy to convert the tumor into an in situ vaccine. Int. J. Radiat. Oncol. Biol. Phys. 84, 879\u2013880 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"32645_CR9","doi-asserted-by":"publisher","first-page":"e1902626","DOI":"10.1002\/adma.201902626","volume":"31","author":"RB Patel","year":"2019","unstructured":"Patel, R. B. et al. Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles. Adv. Mater. 31, e1902626 (2019).","journal-title":"Adv. Mater."},{"key":"32645_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).","journal-title":"Nat. Commun."},{"key":"32645_CR11","doi-asserted-by":"crossref","unstructured":"Demaria, S. et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J. Immunother. Cancer 9, e002038 (2021).","DOI":"10.1136\/jitc-2020-002038"},{"key":"32645_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semradonc.2014.07.004","volume":"25","author":"KA Pilones","year":"2015","unstructured":"Pilones, K. A. et al. Combination of radiotherapy and immune checkpoint inhibitors. Semin. Radiat. Oncol. 25, 28\u201333 (2015).","journal-title":"Semin. Radiat. Oncol."},{"key":"32645_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41551-018-0203-4","volume":"2","author":"K Lu","year":"2018","unstructured":"Lu, K. et al. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nat. Biomed. Eng. 2, 600\u2013610 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"32645_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373\u2013377 (2015).","journal-title":"Nature"},{"key":"32645_CR15","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","volume":"9","author":"Y Yan","year":"2018","unstructured":"Yan, Y. et al. Combining immune checkpoint inhibitors with conventional cancer therapy. Front. Immunol. 9, 1739 (2018).","journal-title":"Front. Immunol."},{"key":"32645_CR16","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845\u20131851 (2018).","journal-title":"Nat. Med."},{"key":"32645_CR17","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen, W. et al. Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5, 1276\u20131282 (2019).","journal-title":"JAMA Oncol."},{"key":"32645_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker, H. E. et al. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409\u2013425 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"32645_CR19","doi-asserted-by":"publisher","first-page":"e1803322","DOI":"10.1002\/adma.201803322","volume":"31","author":"H Phuengkham","year":"2019","unstructured":"Phuengkham, H. et al. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy. Adv. Mater. 31, e1803322 (2019).","journal-title":"Adv. Mater."},{"key":"32645_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale, I. et al. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36\u201350 (2019).","journal-title":"Cell Metab."},{"key":"32645_CR21","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.1021\/acs.nanolett.8b03568","volume":"18","author":"C Shi","year":"2018","unstructured":"Shi, C. et al. Reprogramming tumor-associated macrophages by nanoparticle-based reactive oxygen species photogeneration. Nano Lett. 18, 7330\u20137342 (2018).","journal-title":"Nano Lett."},{"key":"32645_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","volume":"5","author":"K Mehla","year":"2019","unstructured":"Mehla, K. et al. Metabolic regulation of macrophage polarization in cancer. Trends Cancer 5, 822\u2013834 (2019).","journal-title":"Trends Cancer"},{"key":"32645_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A. et al. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399\u2013416 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"32645_CR24","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan, Y. et al. Tumor-associated macrophages in tumor immunity. Front. Immunol. 11, 583084 (2020).","journal-title":"Front. Immunol."},{"key":"32645_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.biomaterials.2016.07.032","volume":"105","author":"AK Hauser","year":"2016","unstructured":"Hauser, A. K. et al. Targeted iron oxide nanoparticles for the enhancement of radiation therapy. Biomaterials 105, 127\u2013135 (2016).","journal-title":"Biomaterials"},{"key":"32645_CR26","doi-asserted-by":"publisher","unstructured":"Song, G. et al. Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv. Mater. https:\/\/doi.org\/10.1002\/adma.201700996 (2017).","DOI":"10.1002\/adma.201700996"},{"key":"32645_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41563-018-0028-2","volume":"17","author":"AW Li","year":"2018","unstructured":"Li, A. W. et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat. Mater. 17, 528\u2013534 (2018).","journal-title":"Nat. Mater."},{"key":"32645_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8556","volume":"6","author":"SA Bencherif","year":"2015","unstructured":"Bencherif, S. A. et al. Injectable cryogel-based whole-cell cancer vaccines. Nat. Commun. 6, 7556 (2015).","journal-title":"Nat. Commun."},{"key":"32645_CR29","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh, S. et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11, 986\u2013994 (2016).","journal-title":"Nat. Nanotechnol."},{"key":"32645_CR30","doi-asserted-by":"publisher","first-page":"e2002054","DOI":"10.1002\/adma.202002054","volume":"32","author":"Y Xia","year":"2020","unstructured":"Xia, Y. et al. Engineering macrophages for cancer immunotherapy and drug delivery. Adv. Mater. 32, e2002054 (2020).","journal-title":"Adv. Mater."},{"key":"32645_CR31","doi-asserted-by":"publisher","first-page":"e1807211","DOI":"10.1002\/adma.201807211","volume":"31","author":"CX Li","year":"2019","unstructured":"Li, C. X. et al. Artificially reprogrammed macrophages as tumor-tropic immunosuppression-resistant biologics to realize therapeutics production and immune activation. Adv. Mater. 31, e1807211 (2019).","journal-title":"Adv. Mater."},{"key":"32645_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","volume":"165","author":"AJ Minn","year":"2016","unstructured":"Minn, A. J. et al. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165, 272\u2013275 (2016).","journal-title":"Cell"},{"key":"32645_CR33","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1073\/pnas.1621363114","volume":"114","author":"H Wang","year":"2017","unstructured":"Wang, H. et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl Acad. Sci. USA 114, 1637\u20131642 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32645_CR34","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.7150\/thno.54881","volume":"11","author":"JC Jagodinsky","year":"2021","unstructured":"Jagodinsky, J. C. et al. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics 11, 6120\u20136137 (2021).","journal-title":"Theranostics"},{"key":"32645_CR35","doi-asserted-by":"publisher","first-page":"638873","DOI":"10.3389\/fonc.2021.638873","volume":"11","author":"Y Kong","year":"2021","unstructured":"Kong, Y. et al. Optimizing the treatment schedule of radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy in metastatic cancers. Front. Oncol. 11, 638873 (2021).","journal-title":"Front. Oncol."},{"key":"32645_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.onc.1210911","volume":"27","author":"AM Krieg","year":"2008","unstructured":"Krieg, A. M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161\u2013167 (2008).","journal-title":"Oncogene"},{"key":"32645_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nrd2059","volume":"5","author":"AM Krieg","year":"2006","unstructured":"Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471\u2013484 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"32645_CR38","doi-asserted-by":"publisher","first-page":"643291","DOI":"10.3389\/fimmu.2021.643291","volume":"12","author":"KM van Pul","year":"2021","unstructured":"van Pul, K. M. et al. Immunotherapy goes local: the central role of lymph nodes in driving tumor infiltration and efficacy. Front. Immunol. 12, 643291 (2021).","journal-title":"Front. Immunol."},{"key":"32645_CR39","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni, M. et al. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front. Immunol. 10, 1084 (2019).","journal-title":"Front. Immunol."},{"key":"32645_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro, F. et al. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front. Immunol. 9, 847 (2018).","journal-title":"Front. Immunol."},{"key":"32645_CR41","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP Bottcher","year":"2018","unstructured":"Bottcher, J. P. et al. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer 4, 784\u2013792 (2018).","journal-title":"Trends Cancer"},{"key":"32645_CR42","doi-asserted-by":"crossref","unstructured":"Miller, H. L. et al. Altered ratio of dendritic cell subsets in skin-draining lymph nodes promotes Th2-driven contact hypersensitivity. Proc. Natl. Acad. Sci. USA 118, 2021364118 (2021).","DOI":"10.1073\/pnas.2021364118"},{"key":"32645_CR43","doi-asserted-by":"publisher","first-page":"e38111","DOI":"10.1371\/journal.pone.0038111","volume":"7","author":"H Zhang","year":"2012","unstructured":"Zhang, H. et al. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS One 7, e38111 (2012).","journal-title":"PLoS One"},{"key":"32645_CR44","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","volume":"10","author":"W Qin","year":"2019","unstructured":"Qin, W. et al. The diverse function of PD-1\/PD-L pathway beyond cancer. Front. Immunol. 10, 2298 (2019).","journal-title":"Front. Immunol."},{"key":"32645_CR45","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu, Q. et al. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell 11, 549\u2013564 (2020).","journal-title":"Protein Cell"},{"key":"32645_CR46","doi-asserted-by":"publisher","first-page":"12579","DOI":"10.1021\/jacs.0c05039","volume":"142","author":"K Ni","year":"2020","unstructured":"Ni, K. et al. Nanoscale metal-organic framework co-delivers TLR-7 agonists and anti-CD47 antibodies to modulate macrophages and orchestrate cancer immunotherapy. J. Am. Chem. Soc. 142, 12579\u201312584 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"32645_CR47","doi-asserted-by":"publisher","first-page":"591139","DOI":"10.3389\/fimmu.2020.591139","volume":"11","author":"WJ Jin","year":"2020","unstructured":"Jin, W. J. et al. Tumor-specific antibody, Cetuximab, enhances the in situ vaccine effect of radiation in immunologically cold head and neck squamous cell carcinoma. Front. Immunol. 11, 591139 (2020).","journal-title":"Front. Immunol."},{"key":"32645_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0952-7915(03)00107-9","volume":"15","author":"JA Trapani","year":"2003","unstructured":"Trapani, J. A. et al. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 15, 533\u2013543 (2003).","journal-title":"Curr. Opin. Immunol."},{"key":"32645_CR49","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1038\/s41388-019-0941-0","volume":"38","author":"F Jallow","year":"2019","unstructured":"Jallow, F. et al. Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer. Oncogene 38, 6913\u20136925 (2019).","journal-title":"Oncogene"},{"key":"32645_CR50","doi-asserted-by":"publisher","first-page":"e2007910","DOI":"10.1002\/adma.202007910","volume":"33","author":"L Sun","year":"2021","unstructured":"Sun, L. et al. ATP-responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity. Adv. Mater. 33, e2007910 (2021).","journal-title":"Adv. Mater."},{"key":"32645_CR51","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1021\/acs.nanolett.0c04772","volume":"21","author":"Z Guo","year":"2021","unstructured":"Guo, Z. et al. Prodrug-based versatile nanomedicine with simultaneous physical and physiological tumor penetration for enhanced cancer chemo-immunotherapy. Nano Lett. 21, 3721\u20133730 (2021).","journal-title":"Nano Lett."},{"key":"32645_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4136-9","volume":"18","author":"T Dovsak","year":"2018","unstructured":"Dovsak, T. et al. Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer. BMC Cancer 18, 235 (2018).","journal-title":"BMC Cancer"},{"key":"32645_CR53","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3389\/fonc.2020.00997","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Low lymphocyte count is associated with radiotherapy parameters and affects the outcomes of esophageal squamous cell carcinoma patients. Front. Oncol. 10, 997 (2020).","journal-title":"Front. Oncol."},{"key":"32645_CR54","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"32645_CR55","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly, R. J. et al. Adjuvant Nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191\u20131203 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32645_CR56","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.7150\/thno.22172","volume":"8","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Metal-based nanoEnhancers for future radiotherapy: radiosensitizing and synergistic effects on tumor cells. Theranostics 8, 1824\u20131849 (2018).","journal-title":"Theranostics"},{"key":"32645_CR57","doi-asserted-by":"publisher","first-page":"753472","DOI":"10.3389\/fimmu.2021.753472","volume":"12","author":"KM Garland","year":"2021","unstructured":"Garland, K. M. et al. Pharmacological activation of cGAS for cancer immunotherapy. Front. Immunol. 12, 753472 (2021).","journal-title":"Front. Immunol."},{"key":"32645_CR58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri3806","volume":"15","author":"J Crouse","year":"2015","unstructured":"Crouse, J. et al. Regulation of antiviral T cell responses by type I interferons. Nat. Rev. Immunol. 15, 231\u2013242 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"32645_CR59","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","volume":"71","author":"BC Burnette","year":"2011","unstructured":"Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488\u20132496 (2011).","journal-title":"Cancer Res."},{"key":"32645_CR60","doi-asserted-by":"crossref","unstructured":"Patel, R. B. et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci. Transl. Med. 13, eabb3631 (2021).","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"32645_CR61","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.3389\/fimmu.2018.02520","volume":"9","author":"E Muller","year":"2018","unstructured":"Muller, E. et al. Both type I and type II interferons can activate antitumor M1 macrophages when combined with TLR stimulation. Front. Immunol. 9, 2520 (2018).","journal-title":"Front. Immunol."},{"key":"32645_CR62","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fimmu.2017.00828","volume":"8","author":"G Genard","year":"2017","unstructured":"Genard, G. et al. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front. Immunol. 8, 828 (2017).","journal-title":"Front. Immunol."},{"key":"32645_CR63","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379\u20135388 (2009).","journal-title":"Clin. Cancer Res."},{"key":"32645_CR64","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"32645_CR65","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.1073\/pnas.91.22.10455","volume":"91","author":"M Haraguchi","year":"1994","unstructured":"Haraguchi, M. et al. Isolation of GD3 synthase gene by expression cloning of GM3 \u03b1\u22122,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl Acad. Sci. USA 91, 10455\u201310459 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32645_CR66","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NA Franken","year":"2006","unstructured":"Franken, N. A. et al. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315\u20132319 (2006).","journal-title":"Nat. Protoc."},{"key":"32645_CR67","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1158\/2326-6066.CIR-19-0338","volume":"8","author":"KA Pilones","year":"2020","unstructured":"Pilones, K. A. et al. Radiotherapy cooperates with IL15 to induce antitumor immune responses. Cancer Immunol. Res. 8, 1054\u20131063 (2020).","journal-title":"Cancer Immunol. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32645-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:59:47Z","timestamp":1669298387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32645-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32645"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32645-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G., Z.S.M., Y.Z. and R.N.S. are inventors on a filed patent (title: nanoparticles for potentiating effects of radiation therapy on anticancer immunotherapy) managed by the Wisconsin Alumni Research Foundation relating to this work. Z.S.M. is a member of the scientific advisory board for Archeus Technologies and Seneca Therapeutics and received equity options for these companies. Z.S.M. is an inventor on patents or filed patents managed by the Wisconsin Alumni Research Foundation relating to the interaction of targeted radionuclide therapies and immunotherapies, nanoparticles designed to augment the anti-tumor immune response following radiation therapy, and the development of a brachytherapy catheter capable of delivering intra-tumor injectables. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4948"}}